4/19/1
DIALOG(R)File 459: Daily Essentials (Archival)
(c) 2007 Prous Science. All rights reserved.

00079630
DISEASE CONTROL NOTED WITH PTK-787/ZK-222584 IN NON-SMALL CELL LUNG CANCER

Daily Essentials
October 16, 2006 (20061016)
Document Type: Congress
Language: English
Record Type: Fulltext ; Image

Preliminary results of a phase II trial of PTK-787/ZK-222584 (PTK/ZK, vatalanib succinate; Schering AG, Novartis) as second-line monotherapy in patients with stage IIIB or IV non-small cell lung cancer showed the drug to be generally well tolerated and to frequently induce disease stabilization. In the study, 56 patients are scheduled to receive 1250 mg once daily and 55 are planned to receive the same dose in a b.i.d. regimen; enrollment in the b.i.d. arm continues. PTK/ZK was generally safe and well tolerated, with nausea, vomiting and dizziness the most common adverse events. Response evaluation (RECIST criteria) for 52 patients treated daily and 3 treated b.i.d. showed 2 with a partial response and 30 with stable disease at week 4. Stable disease for at least 12 weeks was seen in 18 patients, and 1 of 3 patients in the twice daily group had a partial response (Besse, B. et al. Ann Oncol (31st Eur Soc Med Oncol (ESMO) Congr (Sept 29-Oct 3, Istanbul) 2006) 2006, 17(Suppl. 9): Abst 730PD).

Named Companies: Schering AG; Novartis

Named Drugs: Vatalanib succinate; PTK/ZK; PTK-787; ZK-222584 [271217]
Therapeutic Class: Oncolytic Drugs; Antiangiogenic Agents